Dose Insider / Glossary / Ozempic

OzempicWhat it is, what it treats and how it is taken

Updated November 20, 2026 · 4 min read · OZEMPIC prescribing information, revised May 2026

Ozempic is a brand of semaglutide made by Novo Nordisk, best known as a once-weekly injection approved in the United States in 2017 to improve blood sugar control in adults with type 2 diabetes. The name now also covers once-daily Ozempic tablets.

−1.6Ozempic 1 mg, change in HbA1c at week 30
Change in HbA1c at week 30Ozempic monotherapy trial, percentage pointsOzempic 1 mg−1.6Ozempic 0.5 mg−1.4Placebo−0.1Change in HbA1c at week 30Ozempic monotherapy trial, percentage pointsOzempic 1 mg−1.6Ozempic 0.5 mg−1.4Placebo−0.1

70% to 73% reached an HbA1c under 7%, against 28% on placebo.

On this page

Its label also covers lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease, and slowing kidney decline in those with chronic kidney disease. It is not approved for weight loss; the same drug at higher doses is sold for that as Wegovy.1

What it is

Semaglutide copies a gut hormone called glucagon-like peptide-1 (GLP-1) and acts on the same receptor. The label describes three effects behind its action on blood sugar: it increases insulin release when glucose is high, lowers glucagon secretion, and causes a minor delay in the emptying of the stomach after a meal.1 It belongs to the class called GLP-1 receptor agonists.

Ozempic comes as a pen that holds several weekly doses, and as single-dose prefilled syringes. It is injected under the skin of the abdomen, thigh or upper arm, once a week, at any time of day, with or without meals.1

Ozempic tablets are a separate product with their own label, shared with Rybelsus, the older semaglutide tablet. They come in 1.5, 4 and 9 mg and are taken once a day in the morning on an empty stomach with up to 4 ounces of water. Food, drinks and other pills wait at least 30 minutes. They are approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of them. The label warns that Rybelsus and Ozempic tablets are not substitutable milligram for milligram, so a switch between them, or from the injection, follows the prescriber's instructions.2 The rest of this page is about the injection.

What the label approves it for

The label lists three uses, all in adults with type 2 diabetes.1

Weight loss is not on the list. Prescribing Ozempic to someone without type 2 diabetes for weight loss is off-label use. Wegovy, the semaglutide brand approved for weight management, goes up to a weekly 2.4 mg or 7.2 mg; Ozempic stops at 2 mg.1,3

Doses

Treatment starts at 0.25 mg once a week for 4 weeks. The label sets this low start, and the slow climb after it, to reduce the risk of stomach and gut side effects. After that the dose goes to 0.5 mg, and if more control is needed, to 1 mg and then 2 mg, each after at least 4 weeks on the previous dose.1 At the fastest pace the label allows, the first 2 mg dose comes in week 13. Our page on the Ozempic dosing schedule puts the steps on a calendar.

What it did in trials

In the label's 30-week trial of Ozempic on its own, in adults whose diabetes was not controlled by diet and exercise, HbA1c started at about 8%. It fell by 1.4 percentage points on 0.5 mg and 1.6 on 1 mg, against 0.1 on placebo. An HbA1c under 7% was reached by 73% on 0.5 mg and 70% on 1 mg, against 28% on placebo.1

Side effects and warnings

The most common side effects are in the stomach and gut: nausea, vomiting, diarrhea, abdominal pain and constipation. In the label's placebo-controlled trials, nausea was reported by 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo.1

The label carries a boxed warning about thyroid C-cell tumors, which semaglutide caused in rodents; it is not known whether it does so in people. Ozempic must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Other warnings cover pancreatitis, diabetic eye complications, low blood sugar with insulin or a sulfonylurea, kidney injury from fluid loss, gallbladder disease and aspiration during anesthesia.1 Our page on Ozempic side effects gives the rates.

Ozempic in eight lines

FactOzempic
Active ingredientSemaglutide
MakerNovo Nordisk
First U.S. approval2017
How oftenInjection weekly; tablets daily
Injection doses0.25 mg to start, then 0.5, 1 and 2 mg
Half-lifeAbout 1 week
In the body after the last doseAbout 5 weeks
Approved for weight lossNo

OZEMPIC injection prescribing information, revised May 2026; RYBELSUS and OZEMPIC tablets label, revised January 2026.1,2

Ozempic, Wegovy and Rybelsus all contain semaglutide; Rybelsus is the daily tablet for type 2 diabetes that shares its label with Ozempic tablets. Mounjaro and Zepbound contain tirzepatide, which acts on the GLP-1 receptor and a second one, the GIP receptor. Our comparisons of Ozempic and Wegovy and of Ozempic and Mounjaro set the labels side by side.

Sources

  1. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 2, 4, 5, 6.1, 12 and 14. accessdata.fda.gov
  2. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published August 19, 2026; sections 1, 2 and 3. dailymed.nlm.nih.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 2. accessdata.fda.gov

Related analyses

Log each Ozempic dose and see your own week on one screen.

Open Dose Insider